LI KANG BIOMEDICAL Co. Ltd.

LI KANG BIOMEDICAL Co. Ltd.

TTPEX:6242
30.85
TWD
-0.05
(-0.16%)
2.39EPS
15.15P/E
1.16BMarket Cap

Total Valuation

TWD

As of June 30, 2026, LI KANG BIOMEDICAL Co. Ltd. carries a market capitalization of 1.16B, placing it among publicly traded companies globally. Its enterprise value stands at 1.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.16B
Enterprise Value1.14B

Share Statistics

As of June 30, 2026, LI KANG BIOMEDICAL Co. Ltd. has 31.81M shares outstanding.

Shares Outstanding31.81M

Valuation Ratios

As of June 30, 2026, LI KANG BIOMEDICAL Co. Ltd. trades at a trailing price-to-earnings ratio of 15.15. The price-to-sales ratio is 2.02, and the price-to-book ratio stands at 1.37.

PE Ratio15.15
PS Ratio2.02
PB Ratio1.37
P/TBV Ratio1.37
P/FCF Ratio-6.53
P/OCF Ratio15.17

Enterprise Valuation

As of June 30, 2026, LI KANG BIOMEDICAL Co. Ltd. trades at an EV/EBITDA multiple of 12.07 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.99 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.06 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.14B versus a market cap of 1.16B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.99
EV / EBITDA12.07
EV / EBIT13.06

Financial Position

As of June 30, 2026, LI KANG BIOMEDICAL Co. Ltd. maintains a current ratio of 1.04, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.04, indicating elevated leverage, while an interest coverage ratio of 275.73 demonstrates strong ability to service its debt obligations.

Current Ratio1.04
Quick Ratio0.74
Debt / Equity19.04
Debt / EBITDA1.70
Interest Coverage275.73

Financial Efficiency

TWD

Over the twelve months ended June 30, 2026, LI KANG BIOMEDICAL Co. Ltd. posted a return on equity (ROE) of 9.12, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.07 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.78, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.69, useful for judging operating efficiency across full business cycles. The company generates approximately 4.41M in revenue per employee across its workforce of 130.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.62 indicates how many times LI KANG BIOMEDICAL Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)9.12
Return on Assets (ROA)6.78
Return on Invested Capital (ROIC)7.07
Return on Capital Employed (ROCE)7.69
Revenue Per Employee4.41M
Employee Count130.00
Inventory Turnover3.62

Taxes

TWD

Over the twelve months ended June 30, 2026, LI KANG BIOMEDICAL Co. Ltd. recorded 17.16M in income tax expense. That works out to an effective tax rate of 18.34, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 93.55M, leaving 76.39M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax17.16M
Effective Tax Rate18.34

Stock Price Statistics

TWD

As of the close on November 17, 2026, LI KANG BIOMEDICAL Co. Ltd.'s stock has declined approximately 19.97% over the past 52 weeks. The 50-day moving average sits at 33.48, while the 200-day moving average is 36.59.

52-Week Price Change-19.97%
50-Day Moving Average33.48
200-Day Moving Average36.59

Income Statement

TWD

Over the twelve months ended June 30, 2026, LI KANG BIOMEDICAL Co. Ltd. generated 573.36M in revenue and converted that into 76.39M in net income, yielding earnings per share of 2.39. EBITDA reached 94.30M, while operating income came in at 87.19M.

Revenue573.36M
Gross Profit385.44M
Operating Income87.19M
Pretax Income93.55M
Net Income76.39M
EBITDA94.30M
EBIT87.19M
Earnings Per Share (EPS)2.39

Balance Sheet

TWD

As of June 30, 2026, LI KANG BIOMEDICAL Co. Ltd. holds 178.22M in cash and equivalents against 160.52M in total debt, resulting in a net debt position of 43.93M. Total book value stands at 842.86M, with working capital of 10.43M providing operational flexibility.

Cash & Cash Equivalents178.22M
Total Debt160.52M
Net Debt43.93M
Equity (Book Value)842.86M
Book Value Per Share26.50
Working Capital10.43M

Cash Flow

TWD

LI KANG BIOMEDICAL Co. Ltd. produced 76.31M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -254.02M in capital expenditures, free cash flow totaled -177.71M - equivalent to -5.58 per share.

Operating Cash Flow76.31M
Capital Expenditures-254.02M
Free Cash Flow-177.71M
FCF Per Share-5.58

Margins

Over the twelve months ended June 30, 2026, LI KANG BIOMEDICAL Co. Ltd. posted a gross margin of 67.22, reflecting its pricing power and cost economics. The operating margin of 15.21 and net profit margin of 13.32 provide insight into operational efficiency.

Gross Margin67.22
Operating Margin15.21
Pretax Margin16.32
Profit Margin13.32
EBITDA Margin16.45

Dividends & Yields

Over the twelve months ended June 30, 2026, LI KANG BIOMEDICAL Co. Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -15.31: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.38, meaning LI KANG BIOMEDICAL Co. Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-0.38
FCF Yield-15.31

Stock Splits

LI KANG BIOMEDICAL Co. Ltd.'s most recent stock split took place on December 27, 2023 with a 993:1027 split ratio.

Last Split Date12/27/2023
Split Ratio993:1027

Scores

As of June 30, 2026, LI KANG BIOMEDICAL Co. Ltd. has an Altman Z-Score of 3.39, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.39